Ro7851624
Phase 1
RocheRo7851624 is one of 13 therapeutic programs targeting Relapsed/Refractory Multiple Myeloma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
14 competitors in Relapsed/refractory Multiple Myeloma
#DrugCompanyPhaseTrials
1Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
TALVEY
Johnson & JohnsonPhase 1
Tecvayli
Johnson & JohnsonPhase 1
PD-1 Inhibitor
Johnson & JohnsonPhase 1
Darzalex
Johnson & JohnsonPreclinical
Beqalzi
BBeOne Medicines
Preclinical
Kyprolis
VVirionyx Corporation Limited
Preclinical
AZD0120
AstraZenecaPreclinical
Linvoseltamab
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ro7851624. EMBL-EBI & Wellcome Sanger Institute.
- [3]